PIPA5111692

CLEC2A Polyclonal Antibody, Invitrogen™

Manufacturer: Thermo Scientific

Select a Size

Pack Size SKU Availability Price
Each of 1 PIPA5111692-Each-of-1 In Stock ₹ 48,905.50

PIPA5111692 - Each of 1

₹ 48,905.50

In Stock

Quantity

1

Base Price: ₹ 48,905.50

GST (18%): ₹ 8,802.99

Total Price: ₹ 57,708.49

Antigen

CLEC2A

Classification

Polyclonal

Formulation

PBS with 40% glycerol and 0.02% sodium azide; pH 7.2

Gene Accession No.

Q6UVW9

Gene Symbols

CLEC2A

Immunogen

Recombinant Protein corresonding to Human CLEC2A

Quantity

100 μL

Primary or Secondary

Primary

Target Species

Human

Product Type

Antibody

Isotype

IgG

Applications

Immunocytochemistry

Conjugate

Unconjugated

Gene

CLEC2A

Gene Alias

CLEC2A; C-type lectin domain family 2 member A; C-type lectin domain family 2, member A; INPE5792; KACL; Keratinocyte-associated C-type lectin; PILAR; Proliferation-induced lymphocyte-associated receptor; UNQ579; UNQ5792; UNQ5792/PRO19597

Host Species

Rabbit

Purification Method

Antigen affinity chromatography

Regulatory Status

RUO

Gene ID (Entrez)

387836

Content And Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Form

Liquid

Related Products

Img

Thermo Scientific

PIPA5111314

--

Img

Thermo Scientific

PIPA5111359

--

Img

Thermo Scientific

PIPA5111638

--

Img

Thermo Scientific

PIPA5111305

--

Img

Thermo Scientific

PIPA5111488

--

Img

Thermo Scientific

PIPA5111632

--

Img

Thermo Scientific

PIPA5111367

--

Img

Thermo Scientific

PIPA5111396

--

Description

  • Immunogen sequence: IATWSKHAKP VACSGDWLGV RDKCFY CLEC2A (C-type lectin domain family 2 member A), also known as PILAR (proliferation-induced lymphocyte-associated receptor) is involved in modulating T-cell expansion
  • It is a 32 kDa single-pass type II membrane protein that contains one C-type lectin domain in its extracellular region and belongs to the CTL/CTLD superfamily
  • CLEC2A is mainly expressed in skin and highly expressed in CD8(+), B lymphocytes and naive CD4(+) T cells
  • Manipulation of CLEC2A signaling may be important for treatment of autoimmune diseases and cancer.